

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Altress of MMMSSI NEK OF PATENTS AND TRALEMARKS Washington DC (2023) www.iispto.gov

DATE MAILED: 04:22:2003

APPLICATION NO	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09 699,295	10 26 2000	Tony N. Frudakis	210121.419C10	6184
500	590 04 22 2003			
SEED INTELLECTUAL PROPERTY LAW GROUP PLLC 701 FIFTH AVE SUITE 6300			EXAMINER	
			ZEMAN, MARY K	
SEATTLE, WA 98104-7092			ART UNIT	PAPER NUMBER
			1631	~

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
•		09/699.295	FRUDAKIS ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Mary K Zeman	1631				
Period fo	The MAILING DATE of this communication apports.	pears on the cover sheet with the	correspondence address				
THE - Exte after - If the - If NO - Failt - Any	MAILING DATE OF THIS COMMUNICATION. INSIGHT OF THIS COMMUNICA	136(a). In no event, however, may a reply be till ly within the statutory minimum of thirty (30) da will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONI	imely filed ys will be considered timely. In the mailing date of this communication. ED (35 U.S.C. § 133).				
1)	Responsive to communication(s) filed on <u>07</u>	<u>March 2003</u> .					
2a) <u></u> □	This action is FINAL . 2b)⊠ Th	nis action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims							
4)	Claim(s) 3,4,18 and 19 is/are pending in the a	application.					
	4a) Of the above claim(s) is/are withdra	wn from consideration.					
5)	Claim(s) is/are allowed.						
6)[-							
7)	Claim(s) is/are objected to.						
8) 🗌	Claim(s) are subject to restriction and/o	or election requirement.					
Applicat	ion Papers						
9)	The specification is objected to by the Examine	er.					
10)	The drawing(s) filed on is/are: a) acce	pted or b)□ objected to by the Ex a	aminer.				
	Applicant may not request that any objection to the	ie drawing(s) be held in abeyance. S	See 37 CFR 1.85(a).				
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.							
	If approved, corrected drawings are required in re	• •					
12)	The oath or declaration is objected to by the Ex	kaminer.					
Priority (under 35 U.S.C. §§ 119 and 120						
13)	Acknowledgment is made of a claim for foreig	n priority under 35 U.S.C. § 119(a)-(d) or (f).				
a)	☐ All b)☐ Some * c)☐ None of:						
	1. Certified copies of the priority document	ts have been received.					
	2. Certified copies of the priority document	ts have been received in Applicat	tion No				
* (3. Copies of the certified copies of the prio application from the International Bu See the attached detailed Office action for a list	ireau (PCT Rule 17.2(a)).	· ·				
	Acknowledgment is made of a claim for domest	•					
а) The translation of the foreign language pro Acknowledgment is made of a claim for domest	ovisional application has been re-	ceived.				
Attachmen		-					
2) 🔲 Notic	ie of References Cited (PTO-892) ie of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s) <u>1</u>	5) Notice of Informal	ry (PTO-413) Paper No(s) Patent Application (PTO-152)				
S Patent and †	rademark Office						

Application Control Number: 09/699,295

Art Unit: 1631

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 3/7/03 has been entered.

The IDS filed 3/7/03 has been entered and considered. A copy of the form PTO-1449 is enclosed.

Claims 3, 4, 18 and 19 are pending.

The figures of record appear suitable for publication.

Upon updating the search of the elected sequence against the issued patent database, the following art has been identified.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 3, 4, 18 and 19 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 4 and 7-9 of U.S. Patent No. 6,344,550. Although the conflicting claims are not identical, they are not patentably distinct from each other because they both claim the same polynucleotide sequence. SEQ ID NO: 295 of the patent is

Application Control Number: 09/699,295

Art Unit: 1631

95% identical to SEQ ID NO: 301, and would encode a polypeptide that is at least 90% identical to SEQ ID NO: 304, therefore meeting two differing portions of claim 18. Vectors, hosts, and carriers are also claimed.

Conclusion

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary K Zeman whose telephone number is (703) 305-7133.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, can be reached at (703) 308-4028.

Official fax numbers for this Art Unit are: (703) 308-4242, (703) 872-9306. An *unofficial* fax number, direct to the Examiner is (703) 746 5279. Please call prior to use of this number.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the TC1600 Receptionist whose telephone number is (703) 308-0196.

mkz 4/18/03

> HARY IL ZEMAN PRIMARY EXAMINER

W1131